173842-04-1

Basic information

• Product Name: 5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide
• Synonyms: L-757464
• CAS NO: 173842-04-1
• Molecular Formula: C₂₃H₂₄ClN₃O₅S
• Molecular Weight: 489.98183
• Mol File: 173842-04-1.mol

Chemical Properties

• CAS DataBase Reference: 5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide(173842-04-1)
• EPA Substance Registry System: 5-Chloro-2-[4-[4-(2-oxo-2,3-dihydrobenzoxazol-3-yl)piperidin-1-yl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide(173842-04-1)

Safety Data

• Hazardous Substances Data: 173842-04-1(Hazardous Substances Data)

Upstream product

• 215878-20-9 4-[2(3H)-oxobenzoxazol-3-yl]piperidine 
• 95847-42-0 2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H)-one-1,1-dioxide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 95-55-6 2-amino-phenol 
• 162045-53-6 tert-butyl-4-(2-oxobenzo[d]oxazole-3-(2H)-yl)piperidin-1-carboxylate 
• 173841-93-5 1,1-dioxido-2-(4-(4-(2-oxo-3-benzoxazolinyl)-piperidin-1-yl)-butyl)-1,2-benzisothiazol-3(2H)-one 
• 162045-48-9 1-(tert-butoxycarbonyl)-4-[(2-hydroxyphenyl)amino]piperidine 

Relevant articles and documents

Alpha IC adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists

Benign prostatic hyperplasia can be managed pharmacologically with α-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the α-la receptor subtype may offer advantages in clinical applications with respect to hypotensive side effect